DNMT3A and acute myeloid leukemia: The aim of our study was to confirm the prognostic impact of R882 DNMT3A mutations in a series of 288 AML patients treated in our institution and to evaluate its screening usefulness in the medical diagnosis process, in a similar way to KIT exon 17 screening.